Uhmontpellier
Montpellier, 34295, France
NCT Number: NCT04657263
The vaccination policy is drawn up in France by the French Minister of Health, who makes public the vaccination schedule after the opinion of the High Authority of Health.
Currently according to the 2019 immunization schedule, the dTP vaccine is the only mandatory in the general population with recalls in adults aged 25, 45, 65 and every 10 years. In 2011, the Ministry of Health estimated that only 50.5% of the general population was up to date against dTP.
Two vaccines are recommended for person at risk of infection according to the current vaccine schedule: the flu vaccine and the pneumococcal vaccine. In fact, influenza and pneumococcal disease are more frequent and more serious in patients with chronic diseases (diabetes, cardiac insufficiency..) compared to the general population.
The vaccination coverage rate of at-risk populations is dramatically below the vaccination coverage targets set by the Ministry of Health. Indeed, there are many barriers to vaccination, medical and para-medical barriers, but also individual barriers.
The current COVID-19 pandemic has identified people at risk of severe infection and death risk, particularly those with co-morbidities (diabetes, cardiovascular disease, etc.). Thus, this pandemic may have contributed to change in patients' perceptions regarding both the risk of infection and the potential interest and benefit of vaccination.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Montpellier, 34295, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Vaccine coverage assessment
Time frame: 1 day
number of persons at risk of infection up to date with their mandatory and recommended vaccinations during COVID19 pandemic
Time frame: 1 day
Number of persons at risk of infection accepting COVID19 vaccination
University Hospital, Montpellier
Other
Impact of the COVID-19 Pandemic on Vaccination in Patients at Risk of Infection
Acronym: COVIDVacImpac
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04809974
COVID-19, Chronic Disease
Boston, Massachusetts, United States
View Trial DetailsNCT04747990
Acute Pancreatic Fluid Collection, Acute Pancreatic Necrosis
Cagliari, Italy
View Trial DetailsNCT05080920
COVID-19, Cancer
San Sebastián de los Reyes, Madrid, Spain
View Trial DetailsNCT04873349
Blood Coagulation Disorders, Bronchial Diseases
Al Fayyum, Egypt
View Trial Details